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Impaired function of certain mitochondrial respiratory complexes has long been linked to the pathogenesis of chronic
neurodegenerative disorders such as Parkinson’s and Huntington’s diseases. Furthermore, genetic alterations of mitochondrial
genome or nuclear genes encoding proteins playing essential roles in maintaining proper mitochondrial function can lead to
the development of severe systemic diseases associated with neurodegeneration and vacuolar myelinopathy. At present, all of
these diseases lack effective disease modifying therapy. Following a brief commemoration of Professor Albert Szent-Gyo¨rgyi,
a Nobel Prize laureate who pioneered in the field of cellular respiration, antioxidant processes, and the roles of free radicals
in health and disease, the present paper overviews the current knowledge on the involvement of mitochondrial dysfunction
in central nervous system diseases associated with neurodegeneration including Parkinson’s and Huntington’s disease as well
as mitochondrial encephalopathies. The review puts special focus on the involvement and the potential therapeutic relevance
of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1𝛼), a nuclear-encoded master regulator of
mitochondrial biogenesis and antioxidant responses in these disorders, the transcriptional activation of which may hold novel
therapeutic value as a more system-based approach aiming to restore mitochondrial functions in neurodegenerative processes.
1. The Man Amused by the Dance of Electrons
“The fuel of life is electron, or more exactly, the
energy it takes over from photons in photosynthe-
sis, and gives up gradually while flowing through
the cellular machinery.”
This imagination originates from Professor Albert Szent-
Gyo¨rgyi, aHungarian physician and biochemist, former chair
of theDepartment ofMedical Chemistry and theDepartment
of Organic Chemistry at the University of Szeged from
1930 and 1935, respectively, until the end of World War
II in 1945. His early research activities in Groningen and
later in Cambridge conducted on biological combustion,
cellular respiration, and energy production of plants lead
to the discovery of a reducing substance called “hexuronic
acid,” a substance that is able to lose and regain hydrogen
atoms and capable of protecting plants from “browning,”
an injury that he characterized as oxidative damage due
to the excessive activity of an enzyme, peroxidase. This
“antioxidant” substance was later proved by Szent-Gyo¨rgyi
to be equivalent with a potent antiscorbutic (antiscurvy)
agent and was given the name ascorbic acid, currently widely
known as vitamin C, which is most abundant in citrus fruits
and paprika, an emblematic vegetable of Szeged. At this time,
performing ongoing research in the field of biological respi-
ration, Szent-Gyo¨rgyi discovered and identified the catalysis
of fumaric acid among other steps of the tricarboxylic acid
cycle (also referred to as Szent-Gyo¨rgyi–Krebs cycle, citric
acid cycle), an essential component of cellular respiration
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that provides reducing equivalents for terminal oxidation
and thereby energy production from metabolic products of
dietary macromolecules. “For his discoveries in connection
with the biological combustion processes, with special reference
to vitamin C and the catalysis of fumaric acid,” Albert
Szent-Gyo¨rgyi was awarded Nobel Prize in Physiology or
Medicine in 1937. In addition to his pioneering work in mus-
cle research—including the discovery of actin and myosin
proteins and the mechanism of their joint function—as well
as the discovery of vitamin P (flavanone), his subsequent
research interests focused on the interactions of proteins
and free radicals and their role in regulating cell division
and cancer development, and he published a number of
books and papers about his findings and scientific theories
of bioenergetics and bioelectronics and their roles in health
and disease.
Following the imaginations of our honored predecessor,
this paper reviews the concepts on the role of impairments
inmitochondrial respiration and subsequent excessive oxida-
tion in degenerative central nervous system (CNS) disorders,
with special attention to recent findings related to alterations
in transcriptional regulation of mitochondrial biogenesis and
bioenergetics, and their potential therapeutic relevance.
2. Mitochondrial Respiration: The Proper
Function of a Dangerous System
Mitochondria are membrane-bound intracellular organelles
evolutionary originating from the endosymbiosis of an
ancient aerobic alpha-proteobacterium with an early eukary-
otic host cell [1]. Harboring their own maternally inherited,
double-stranded, circular genome (mtDNA), supplemented
by the presence of several ancillary, structural, and regulatory
proteins encoded by the nuclear DNA (nDNA), mitochon-
dria host a number of molecular processes essential for
cellular life and death. These include processes related to
the production of biologically utilizable energy, adaptive
thermogenesis via the uncoupling of energy production, as
well as the regulation of cellular calcium homeostasis, cell-
cycle, and programmed cell death.
Energy production in the mitochondria is performed
through the coupled function of pyruvate dehydrogenase
complex (PDC),𝛽-oxidation (processes essential in glycolytic
and ketogenic metabolism, resp.), the Szent-Gyo¨rgyi–Krebs
cycle, and the terminal oxidation and oxidative phosphory-
lation (OXPHOS). While PDC, 𝛽-oxidation, and the Szent-
Gyo¨rgyi–Krebs cycle take place within the mitochondrial
matrix, terminal oxidation and OXPHOS are linked to the
function of respiratory complexes I–V (electron transport
chain, ETC) embedded in the inner mitochondrial mem-
brane.The process of energy production has been extensively
reviewed elsewhere [2, 3]. Briefly, glucose is catabolized in
the cytosol to yield pyruvate through multiple enzymatic
steps of the glycolysis, which is then translocated into the
mitochondria andmetabolized to acetyl-coenzymeA (acetyl-
CoA) by PDC. On the other hand, fatty acids are oxi-
dized during the 𝛽-oxidation to acetyl-CoA entirely within
the mitochondria (or in case of longer-chain fatty acids,
initially within the peroxisomes). Mitochondrial acetyl-
CoA subsequently enters the Szent-Gyo¨rgyi–Krebs cycle to
form reduced coenzyme NADH and succinate in multiple
steps, which in turn provide electrons for respiratory com-
plex I (NADH dehydrogenase) and complex II (succinate-
ubiquinone oxidoreductase), respectively, using FMN and
FAD as prosthetic groups, respectively.The electrons are then
transported fromboth complexes via themobile carrier coen-
zyme Q (ubiquinone) to complex III (ubiquinol-cytochrome
𝑐 oxidoreductase) and flow through cytochrome 𝑐 to reach
complex IV (cytochrome 𝑐 oxidase) to be oxidized by the
final electron acceptor, oxygen. Notably, reducing equivalents
produced during the glycolysis (in form of NADH) can also
be translocated to the mitochondria via the malate/aspartate
shuttle and the glycerol phosphate shuttle to provide NADH
and FADH
2
, respectively, which in turn, similarly to NADH
and FADH
2
produced during 𝛽-oxidation, feed the ETC at
complex I and coenzyme Q, respectively. Within the ETC,
respiratory complexes are arranged in an electrochemical
order, corresponding to their gradually increasing redox
potential and electronegativity.The flow of electrons through
the respiratory complexes provides energy used to pump
out protons through complexes I, III, and IV (cytochrome 𝑐
oxidase) to the intermembrane space. At the end of the down-
stream flow of electrons, molecular respiratory oxygen as the
final electron acceptor is reduced by complex IV to form
water molecule in a process known as terminal oxidation.
The release of protons from the matrix develops a gradient
of protons between the matrix and the intermembrane space
also referred to as mitochondrial membrane potential (neg-
ative inside) as well as an electrochemical gradient (alkaline
inside). Being impermeable to protons, the inner membrane
works as a capacitator and an electric insulator. Therefore,
the electrochemical drive to equalize the concentration of
protons can be satisfied by the reentry of protons through
respiratory complex V (H+-ATP synthase), the subsequent
activation of which leads to the formation of ATP from
ADP in a process called OXPHOS. The produced ATP
represents a biologically available form of electrochemical
energy, serving as the main energy-provider for eukaryotic
cells (Mitchell’s chemiosmotic hypothesis) [4]. The energy
stored in mitochondrial membrane potential (also known as
“proton motive force”) can also be utilized to generate heat
or to import calcium or proteins into the mitochondrion via
uncoupling the transport of electrons from ATP production,
which processes serve adaptive purposes. The proportion
of dietary calories burnt within the mitochondrion and
allocated to energy production is referred to as “coupling
efficiency.”
In multicellular organisms, the ability to adaptively regu-
late and activate mitochondrial biogenesis and functions in
response to a variety of conditions is essential to maintain
energetic homeostasis and cellular viability. Several lines of
evidence obtained in the past decade suggest that peroxisome
proliferator-activated receptor-gamma (PPAR𝛾) coactivator
1-alpha (PGC-1𝛼), a nuclear-encoded coactivator of a wide
range of transcriptional factors, plays a key role in the
transcriptional cascade of such adaptive processes. PGC-1𝛼-
mediated coactivation of genes such as nuclear respiratory
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Figure 1: The PGC-1𝛼 cascade. Transcriptional upregulation or posttranslational activation of PGC-1𝛼 due to fasting, physical exercise,
cold exposure, or pharmacological manipulations leads to the transcriptional activation of several nuclear-encoded proteins involved in
mitochondrial functioning at multiple levels, including mitochondrial biogenesis, adaptive metabolism, antioxidant responses, and proper
ETC assembly/import.
factor 1 and 2 (NRF-1, -2), PPARs, estrogen-related receptors
(ERRs), and myocyte-specific enhancer factor 2C (MEF2C)
leads to an increased expression of a wide range of proteins
involved in mitochondrial transcription, replication, and the
import and assembly of a number of nuclear-encoded respira-
tory complex subunits; furthermore, it boosts OXPHOS and
thermoregulation in a tissue-dependent manner, enhances
gluconeogenesis and fatty acid oxidation [5], and increase
oxidative stress defense [6] (Figure 1). The inducing effect
of physical exercise (mediated by calcineurin A-linked MEF2
activity, calcium/calmodulin-dependent protein kinase IV-
(CaMKIV-) linked cyclic AMP (cAMP) response element-
binding protein (CREB) activity, and a p38mitogen-activated
protein kinase- (MAPK-) linked activating transcription
factor 2 (ATF-2) activity), cold exposure and starvation
(mediated by catecholamine- and glucagon-induced cAMP
elevation and a subsequent phosphorylation and activation
of CREB by protein kinase A (PKA)) on PGC-1𝛼 expression
is well documented [5]. Furthermore, energy deprivation
through a high AMP/ATP ratio leads to an increased AMP-
activated protein kinase (AMPK) activity and a subsequent
phosphorylation of PGC-1𝛼 protein, priming PGC-1𝛼 for
subsequent deacetylation and thereby activation by silent
information regulator 2 homolog 1 (Sirt-1) [7, 8], the expres-
sion of which is also increased in conditions with energy
shortage, such as, starvation or exercise, due to a high
NAD+/NADH ratio [9]. These posttranslational modifica-
tions on PGC-1𝛼 play pivotal roles in adaptive mitochondrial
biogenesis.The roles of impairedmitochondrial function and
more recently a decreased function of the PGC-1𝛼 cascade
in the pathogenesis of degenerative CNS disorders are of
extensive research interest.
3. Mitochondrial Dysfunction, Reactive
Oxygen, and Nitrogen Species
Free radicals are molecules possessing unpaired electrons in
their outer orbit. This renders them highly reactive towards
organicmacromolecules such as carbohydrates, nucleic acids,
proteins, and lipids, which suffer “injury” during such a
reaction. The main routes of free radical production and
subsequent toxic insults are represented in a schematic
depiction in Figure 2. Under physiological conditions, the
efficiency of reducing oxygen during terminal oxidation
is approximately 97–99%, while 1–3% undergo incomplete
reduction to superoxide (O2
∙−), a highly reactive free radical.
O2
∙− can be transformed into hydrogen peroxide (H
2
O
2
)
both spontaneously and through a reaction catalyzed by
mitochondrial manganese superoxide dismutase (Mn-SOD)
in the matrix. H
2
O
2
normally undergoes degradation by
glutathione peroxidase (GPX) and catalase (CAT) enzymes,
yielding water. In case of an impaired function of the mito-
chondrial ETC, leakage of excess electrons from complexes
I and III leads to a higher amount of O2
∙− and subsequent
H
2
O
2
production, which when exceeding the degradative
capacity of the mitochondria can be transformed into the
extremely toxic hydroxyl radical (HO∙), through reaction
with transition metals (Fe2+ and Cu2+; Fenton reaction).
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Figure 2: Schematic representation of the generation and the effects of free radicals within themitochondria.The leakage of electrons from the
mitochondrial ETC at complexes I and III results in the formation of superoxide anion.The high reactivity of this molecule evokes a harmful
cascade mechanism including the formation of reactive oxygen and nitrogen species. The cascade mechanism deteriorates the functional
groups of major components of all kinds of biomolecules (carbohydrates, lipids, proteins, and nucleic acids). In case of pronounced electron
leakage or deficient antioxidant protection, a vicious circle of mitochondrial dysfunction develops.
HO∙ in turn can react with nucleic acids and phospho-
lipids, yielding the formation of further toxic radicals and
consequent severe functional impairments of the affected
macromolecules. Furthermore, HO∙ can also react with thiol
residues, yielding the formation of multiple reactive free
radicals. In addition, O2
∙− can also react with nitric oxide
(NO∙) generated from L-arginine by mitochondrial nitric
oxide synthase (mtNOS) enzyme [10]; however, other sources
of mitochondrial NO∙ associated with nitrite reductase activ-
ity under hypoxic conditions have also been identified [11–
13]. The reaction of NO∙ with O2
∙− yields the highly toxic
peroxynitrite anion (ONOO−) in a reaction that is three times
as fast as the dismutation of O2
∙− by Mn-SOD. ONOO− can
evoke injury to proteins via nitration of tyrosine, tryptophan,
and phenylalanine residues by nitronium ion (NO2
+) gen-
erated through metal-peroxynitrite (ONOO−Me𝑛X) com-
plexes. Nitration of tyrosine can also be achieved by serial
reactions of further pathways involving ONOO− and NO∙
(see Figure 3 for detailed description). Nitrosylation of thiol,
secondary amine, alcohol, and alkane residues are performed
via their reaction with nitrosonium ion (NO+) or indirectly
with dinitrogen trioxide (N
2
O
3
), highly reactive radicals also
derived from NO∙. Furthermore, NO∙ can directly impair
the mitochondrial ETC and OXPHOS via competing with
oxygen for the oxygen-binding site of complex IV [14], which
leads to a further increase in free radical production.
The toxic radicals described above are known as reactive
oxygen species (ROS) and reactive nitrogen species (RNS),
and their damaging effects on macromolecules are referred
to as oxidative and nitrative/nitrosative stress, respectively.
Figure 3 presents a detailed overview on the molecular
background of toxic processes related to ROS and RNS.
With mitochondrial ETC being the main source of ROS
and RNS production, macromolecular components of the
mitochondria are extremely exposed to injury due to oxida-
tive/nitrative/nitrosative stress. Of note, proteins that under-
went such a damage are highly susceptible to proteolytic
cleavage and degradation [15]. The injury to mitochondrial
respiratory complex subunits by impaired efficacy of the ETC
has two main consequences: (1) it leads to decreased energy
production due to impaired OXPHOS, and (2) it decreases
the efficacy of terminal oxidation, which results in increased
production of ROS/RNS, generating a vicious circle.
The proximity to the main source of free radical
production and the relatively high proportion of coding
sequences render the mitochondrial genome particularly
sensitive to ROS/RNS-mediated injury [16]. Indeed, the
mutation rate of mtDNA relative to nDNA is approximately
10 : 1 [17]. Furthermore, as the ability to cope with oxida-
tive/nitrative/nitrosative stress declines with aging [18], the
rate ofmtDNAmutations further increases in the elderly [19].
Excessive ROS and RNS accumulation can trigger the
opening of mitochondrial permeability transition pores
(mtPTP), which on the one hand decreases the mitochon-
drial membrane potential further aggravating the initial
OXHPHOS impairment, and, on the other hand, leads to
the release of proapoptotic factors (including apoptosis-
inducing factor, procaspase-9, and cytochrome 𝑐) from the
intermembrane space to the cytosol. This is in severe cases
followed by cellular death that can be either apoptotic or
necrotic, depending on the severity of the initial insult and
subsequent energy deprivation [20–22]. It should be noted,
however, that being among the most ancient signals between
mitochondria and their host cells, both ROS and RNS might
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Figure 3: The detailed depiction of the chemistry of mitochondrial oxidative and nitrative/nitrosative stresses. The contents of the colored
bubbles correspond to the processes indicated in the bubbles of the respective color in Figure 2. Figure 3 presents the chemical processes
of ETC and the terminal oxidation (white bubble; blue Roman numbers represent the site of the respective respiratory complexes) together
with those involved in the generation of ROS (light blue bubble) and RNS (yellow bubble). An overview is given on the most representative
molecules involved in oxidative injury to nucleic acids (brown bubble), lipids (pink bubble), andmolecules with thiol residues (green bubble),
as well as in nitrosylation/nitration of organic macromolecules (yellow bubble). For detailed explanation of oxidative/nitrative/nitrosative
(black) and antioxidant (green) processes as well as the function of the ETC (red), we refer to the corresponding sections within the text and
the Abbreviations section.
have essential physiological functions under physiological
conditions.
Defensive processes of the mitochondria to counteract
excessive free radical production involve low molecular
weight antioxidants (LMWAs), an enzymatic redox apparatus
to clear ROS/RNS (e.g., SOD, CAT, GPX, and peroxiredoxin),
and an nDNA-encoded repair machinery.
Ubiquinol and tocopherols represent the main groups of
lipid-associated LMWAs. Since these molecules are trans-
formed to semiquinone radicals upon reduction of toxic
free radicals, the immediate restoration of antioxidant capac-
ity is essential. This process depends on the standard
redox potential of LMWAs. For example, reduction of the
semiquinone form of lipid-associated tocopherol requires
ascorbic acid (vitamin C, identified by Albert Szent-Gyo¨rgyi)
and the subsequent reduction of the produced ascorbic acid
radical by glutathione. Therefore, at the end of the process,
no free radicals are present. However, there is a need for
the restoration of the reduced glutathione, which is medi-
ated by the enzyme glutathione reductase (Gred). Reduced
glutathione also participates in antioxidant functions asso-
ciated with the activities of SOD and GPX (including the
phospholipid-associated form (PHGPX) as well), and it is
responsible for the detoxification of HO∙ and ONOO−. The
proper function of this armatory requires the appropriate
load of reducing equivalents (NADH + H+, NADPH + H+).
The above mechanisms are depicted in Figure 3.
A number of evidence link PGC-1𝛼 to the regulation
and activation of mitochondrial antioxidant responses. In a
comprehensive study of St-Pierre et al. [6], the expression
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of PGC-1𝛼 significantly increased after H
2
O
2
challenge in
10T1/2 cells, which effect was recapitulated by Irrcher et al. on
C
2
C
12
muscle cells [23].This effect is in correspondence with
our recent findings of significantly increased PGC-1𝛼 expres-
sion in the CNS of mice intoxicated with the neurotoxin
3-nitropropionic acid, an irreversible inhibitor or complex
II [24]. Furthermore, RNAi against PGC-1𝛼 reduced the
baseline expression of copper/zinc (Cu/Zn)-SOD, Mn-SOD,
and GPX in 10T1/2 cells, whereas the expression of Cu/Zn-
SOD, Mn-SOD and peroxisomal CAT was found reduced in
the heart and brain of PGC-1𝛼-deficient mice [6]. Similarly,
overexpression of PGC-1𝛼 in C
2
C
12
myotubes displayed
increased expression of Mn-SOD and GPX in association
with a decreased amount of ROS production [25]. Moreover,
PGC-1𝛼-deficient fibroblasts exhibited blunted response to
ROS challenge and an increased sensitivity to oxidative stress,
which was in correspondence with an increased sensitivity
of PGC-1𝛼-deficient mice to intoxication with 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an irreversible
inhibitor of mitochondrial respiratory complex I, as well as to
that with the excitotoxin, kainate [6].
Mitochondrial repair is now widely-acknowledged as an
existing phenomenon, comprising a group of processes that
aim to repair deleterious alterations in mtDNA, predom-
inantly due to oxidative injuries. These include enzymatic
apparatuses for (1) the hydrolysis of oxidized deoxyribonu-
cleotide triphosphates to prevent mismatch errors, (2) differ-
ent mechanisms of single- and double-strand break repair,
(3) multiple mechanisms of base excision repair, and (4) the
degradation of unrepairable mtDNA. The latter is a unique
mitochondrion-specific mechanism in eukaryotes, which is
enabled by the redundance of mtDNA within the organelle
[26]. Certain evidence suggest that, similarly to that seen
in nDNA repair, poly(ADP-ribose) polymerase-1 (PARP-1)
might play central role of the epigenetic regulation of nDNA-
encoded proteins involved in mtDNA repair mechanisms
[27].
In case the antioxidant defense and repair systems prove
insufficient to protect the organelle, severely damaged mito-
chondria can be sensed and degraded by a process under the
regulation of PINK1 and parkin (mitophagy) [28, 29].
4. The Central Role of Mitochondrial
Dysfunction in Neurodegenerative Diseases
Anumber of general observations and considerations explain
the special susceptibility of the CNS to suffer injuries due to
mitochondrial disturbances. Indeed, the CNS has an espe-
cially high energy demand as it represents merely 2% of the
total body mass and accounts for some 20% of bodily oxygen
consumption [30]. Besides, unlike astrocytes, neurons store
low amounts of glycogen and have a poor ability to enhance
glycolysis under conditions when mitochondrial respiration
is impaired [31]. Therefore, neurons depend on the constant
availability of oxygen and glucose tomaintain their functions.
Furthermore, the CNS contains high amounts of polyun-
saturated lipids, which are highly susceptible to oxidative
injury by means of lipid peroxidation, and the antioxidant
capacity of neurons is known to be relatively poor [32, 33].
The high sensitivity of neurons as opposed to the relative
resistance of astrocytes to oxygen or glucose deprivation is
well known; however, recent studies suggest that oligoden-
drocytes are among the most sensitive cell types within the
CNS to mitochondrial stress, exceeding the vulnerability of
neurons [34, 35], a feature that may have implications for
the pathogenesis of characteristic myelinopathies in chronic
conditions with mitochondrial dysfunction, including aging,
and mitochondrial encephalopathies.
Another CNS-specific mechanism leading to an in-
creased sensitivity to mitochondrial dysfunction is excitotox-
icity due to glutamate, the major excitatory neurotransmitter
in the brain [36]. In an event of energy deprivation, neurons
undergo partial membrane depolarization, which removes
magnesium ions that block the ionophore of N-methyl-D-
aspartate-sensitive (NMDA) glutamate receptors. This leads
to a persistent activation of NMDA receptors by glutamate
even if it is present in physiological levels [37]. Hyperactiva-
tion of NMDA receptors results in an influx of calcium into
the cytosol. The persistent increase in intracellular calcium
level leads to an increased mitochondrial sequestration of
calcium, which in pathological extents evokes the opening
of high-conductancemtPTPs [38], resulting inmitochondrial
swelling and a decreasedmitochondrial membrane potential,
with subsequent OXPHOS impairment and ROS overpro-
duction [39]. These culminate in the release of proapoptotic
factors eventually triggering cell death [40] by apoptotic or
necrotic mechanisms, based on the severity of the event
[20, 21]. It has also been postulated, however, that the mech-
anism and the channel (i.e., NMDA receptor) through which
calcium ions get into the cell and not the calcium overload
itself may play the pivotal roles in excitotoxic cell death
[41]. Indeed, NMDA receptors are functionally and spatially
linked to neuronal NOS (nNOS) by postsynaptic density
protein of molecular weight 95 kDa (PSD-95) that synthesize
NO∙ in a toxic amount while calcium ions enter into the cell
during NMDA receptor overactivation [42]. Notably PSD-95
attaches to the NR2B subunit, which is in correspondence
with the observation that glutamate excitotoxicity is pre-
dominantly mediated by NR2B subunit-containing NMDA
receptors [43], which are mainly located extrasynaptically
[44]. In line with these, activation of extrasynaptic NMDA
receptors is regarded as neurotoxic, whereas that of the
synaptic NMDA receptors appears to be neuroprotective
[45, 46], indicating a role of volume transmission in NMDA
receptor-mediated neurotoxicity. A central role of nNOS
in excitotoxic injury was suggested by earlier studies as
well [47, 48]. The role of excitotoxicity in association with
mitochondrial dysfunction as well as the possible therapeutic
relevance of approaches aiming to counteract glutamater-
gic overactivation in neurodegenerative diseases, including
pharmacological manipulations with the kynurenine system,
have recently been extensively reviewed [49, 50] and are not
within the scope of this review.
The following subsections emphasize the relevance of
mitochondrial dysfunction in the pathomechanism of degen-
erative CNS disorders through a detailed overview on the
involvement of impairedOXPHOS andmitochondrial bioen-
ergetics in Parkinson’s disease, Huntington’s disease, and
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Figure 4: The involvement of mitochondrial dysfunction in Parkinson’s disease. Complex I deficiency, the predominant electron transport
disorder in sporadic PD has long been linked to the deleterious effects of 𝛼-synuclein aggregation, a pathognomonic alteration in PD,
and inhibitors of complex I (such as MPTP, rotenone, and paraquat) are used in experimental modeling of the disease. Since then a
number of genes have been associated with familial forms of the disease, many of them having direct implications in mitochondrial
dysfunction. Disturbed OXPHOS in the affected cells can lead to the development of a vicious circle, eventually leading to cell death. Novel
findings link PGC-1𝛼 dysfunction to the pathogenesis of sporadic PD, the restoration of which may hold therapeutic value. (↑ = increased
presence/expression/activity; ↓= decreased presence/expression/activity; arrow= promotion; bulb-headed arrow= inhibition/deterioration.)
mitochondrial encephalopathies, with special focus on the
involvement and therapeutic relevance of PGC-1𝛼.
4.1. Parkinson’sDisease. Parkinson’s disease (PD) is a progres-
sive, chronic neurodegenerative disorder, the pathognomonic
alterations of which include loss of dopaminergic neurons,
and the presence of Lewy bodies in the substantia nigra
pars compacta (SNpc), with a subsequent decrease in striatal
dopamine levels [51]. Leading clinical symptoms include
bradykinesia, rigidity, resting tremor, and postural instability
[52, 53], eventually evolving into severe akinesia, dementia,
and eventually death. The development of sporadic PD is
linked to a complex interplay of genetic and environmental
factors, which have multiple implications for mitochondrial
involvement (Figure 4). The first implication for the role of
mitochondrial dysfunction in PD came from serial cases
of intoxication by the side-product of a synthetic illicit
drug, MPTP, which evokes parkinsonian symptoms and
recapitulates the majority of PD-related pathologies [54].
Its active metabolite 1-methyl-4-phenylpyridinium (MPP+)
selectively and irreversibly impairs the function of mito-
chondrial complex I in dopaminergic neurons [55, 56], and
since its discovery, systemic MPTP or intraventricular MPP+
intoxication became the most widely applied in vivo toxin
models of PD. Similar effects can be achieved by known
environmental chemicals including the herbicide paraquat
and the insecticide rotenone [57]. Corresponding with the
ability of complex I inhibitors to evoke parkinsonism, a
decreased activity and/or expression of respiratory complex
I has been detected in the SNpc [58, 59], striatum [60] frontal
cortex [61], platelets [62, 63], and skeletal muscle [64, 65]
of sporadic PD patients, suggesting a systemic impairment
of mitochondrial functions in this disease. Less consistent
reports have been published regarding the involvement of
other respiratory complexes, which indicates a predominant
involvement of complex I in sporadic PD. In line with these,
a decreased activity of complex I, an elevated production of
ROS, an energy impairment, and an increased sensitivity to
MPP+ intoxication can be detected in PD cybrids [66, 67].
The increased presence of oxidative damage has also been
reported in post mortem SN of PD patients [68, 69].
In the past decades, genetic and, more recently, genome-
wide association studies (GWAS) have identified over 20 loci
in causative association with familial PD [70], many of them
having direct implications in mitochondrial dysfunction.
Among them, leucine-rich repeat kinase 2 (LRRK2) protein
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is known to colocalize with membrane bound intracellu-
lar structures including mitochondria [71]. Its autosomal
dominantly inherited mutation, G2019S, the most frequent
underlying genetic alteration in both familial and sporadic
PD cases, has been associated with mitochondrial dysfunc-
tion and morphological alterations in PD tissue samples
[72], abnormal mitochondrial dynamics and increased ROS
production in murine primary cortical neurons [73], as well
as with an increased neuronal vulnerability to rotenone and
paraquat in a nematode model of PD [74].
The autosomal dominantly inherited mutation of SNCA
gene (A53T) leads to mitochondrial accumulation of 𝛼-
synuclein, the main constituent of Lewy bodies, resulting in
the inhibition of respiratory complex I [75, 76]. The protein
appears to play pivotal roles in modulating oxidative stress,
as its transgenic overexpression leads to enhanced sensitivity
against intoxication with paraquat and MPTP [77], whereas
𝛼-synuclein-deficiency leads to resistance against intoxica-
tion with MPTP, 3-nitropropionic acid and malonate in mice
[78] (the latter two are inhibitors of complex II and serve
as toxin models for Huntington’s disease). Accordingly, cell
lines transfected with mutant 𝛼-synuclein exhibit increased
levels of oxidation products, decreased glutathione levels, and
a markedly increased cell death in response to toxic insults
including H
2
O
2
and MPP+ exposure [79].
Among genes associated with an autosomal recessive
inheritance of familial PD, parkin, a ubiquitin E3 ligase, is
responsible for the polyubiquitin tagging of toxic protein
aggregates for proteasomal degradation [80]. In addition,
parkin appears to be involved in antioxidant functions
through regulating SOD activity and glutathione levels [81]
and may play important roles in mitochondrial transcription
via its association with mitochondrial transcription factor
A (Tfam) [82]. Accordingly, parkin-deficient mice display
decreased expression of complex I and IV subunits accom-
panied by a diminished antioxidant capacity and enhanced
oxidative damage [83], whereas parkin-deficient flies develop
abnormal mitochondria and exhibit an increased vulnerabil-
ity to paraquat [84]. Among in vitro conditions, overexpres-
sion of wild-type parkin reduced, whereas that of the mutant
allele aggravated cell death induced by different oxidative
stimuli includingH
2
O
2
andMPP+ intoxication, which aggra-
vationwas accompanied by increased levels of oxidative stress
markers and a decreased amount of glutathione [85]. In line
with these, transfection of cell lines with mutant parkin leads
to an increased presence of markers of oxidative and nitrative
injuries [86]. Notably, however, the potential of wild-type
parkin overexpression to protect against oxidative insults in
vitro has been challenged [87], and another study found
no increase in vulnerability to different regimens of MPTP
exposure in parkin-deficient mice [88].
Parkin appears to share common pathway with phos-
phatase and tensin homologue- (PTEN-) induced putative
kinase 1 (PINK1), another protein associated with autoso-
mal recessive PD, with PINK1 acting upstream of parkin
[89]. Indeed, both proteins are involved in the regula-
tion mitochondrial dynamics [28, 29, 90, 91], and pheno-
types associated with PINK1-deficiency have been repeat-
edly reported to be rescued by parkin [89, 92–94]. In
experimental models, PINK1-deficiency has been associated
with impaired mitochondrial respiration (most consistently
complex I deficiency) [95, 96], decreased energy production
[92, 93, 97, 98], elevated ROS production [98, 99], impaired
mitochondrial calcium handling [98–100], mitochondrial
morphological alterations [28, 29, 89–91, 93, 98], and an
increased susceptibility to mPTP [99–101]. Furthermore,
PINK1-deficiency exacerbates neurodegeneration evoked by
MPP+ in vitro andMPTP in vivo [102]. In addition to parkin,
tumor necrosis factor (TNF) receptor-associated protein 1
(TRAP1), a mitochondrial molecular chaperone also known
as heat shock protein 75 (Hsp75), has been postulated to
be another possible downstream target of PINK1, through
which PINK1 activity can prevent the release of cytochrome 𝑐
and a subsequent apoptosis [103]. The functional association
between TRAP1 and PINK1 has gained further support by
more recent studies [104, 105], consistently suggesting that
TRAP1 acts downstream of PINK1 and in parallel with parkin
when mediating amelioration in mitochondrial dysfunction.
Mutations of DJ-1, an oxidative stress sensor capable
of modulating glutathione metabolism and mitochondrial
transcription under mitochondrial stress [106], leads to auto-
somal recessive familial PD.The protein is suggested to func-
tion in parallel with PINK1/parkin pathway in maintaining
mitochondrial function among oxidative conditions [107].
At the experimental level, DJ-1-deficiency has been asso-
ciated with increased ROS production [108–110], impaired
mitochondrial respiration [109] or energy production [110],
mitochondrial morphological abnormalities [109], increased
opening of the mPTP [110], as well as an increased sensitivity
to oxidative stressors including MPTP [111], paraquat [112],
and H
2
O
2
[112].
Apart from genes identified in monogenic familial PD,
a number of genes have been associated with the develop-
ment of sporadic PD as modifying or susceptibility factors,
including genes involved in mitochondrial functions such as
mtDNApolymerase gamma 1 (POLG1) [113, 114] and complex
I subunit ND5 [115]. In addition to these, an increasing body
of evidence suggests that PGC-1𝛼may add important contri-
butions to the pathogenesis of PD. Indeed, a comprehensive
genome-wide meta-analysis found a set of 425 PGC-1𝛼-
responsive nuclear-encoded mitochondrial genes underex-
pressed in sporadic PD, representing pinpoint defects in glu-
cosemetabolism andmitochondrial ETC [116]. Furthermore,
associations of single nucleotide polymorphisms (SNPs) of
PGC-1𝛼 have been reported with the risk of PD, the age of
onset and the longevity [117].These appear to be in correspon-
dence with decreased expression of PGC-1𝛼 and its target
gene NRF-1 in the SN and striatum of PD patients as well as
in the midbrain of conditional parkin knockout mice [118].
In line with decreased ATP production and impairments
in mitochondrial OXPHOS [119] and antioxidant responses
[6], PGC-1𝛼-deficient mice display enhanced susceptibility
to MPTP toxicity [6]. Corresponding to observations that
mitochondrial dysfunction can promote the aggregation of
𝛼-synuclein [120], reduced expression of PGC-1𝛼 in vitro
lead to enhanced 𝛼-synuclein oligomerization [121]. This
effect was, however, not confirmed in PGC-1𝛼-deficient
mice, suggesting a more complex scenario for mitochondrial
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dysfunction-induced 𝛼-synuclein aggregation in vivo [122].
Supporting a potential therapeutic relevance in PD, overex-
pression of PGC-1𝛼 demonstrated neuroprotection against
𝛼-synuclein- and rotenone-induced toxicity in vitro [116]
and in a parkin interacting substrate (PARIS) overexpression
model of PD in vivo [118]. In line with these, transgenic
overexpression and resveratrol-induced activation of PGC-1𝛼
(via deacetylation by Sirt-1) both rendered neuroprotection
against MPTP toxicity in mice [123]. Similarly, the adminis-
tration of pioglitazone, an agonist of PPAR𝛾 that enhances the
activity and expression of PGC-1𝛼 [124], was also protective
in MPTP studies [125, 126]. These altogether suggest that
a deficient expression and/or function of PGC-1𝛼 and its
target genes may play important roles in the development
of sporadic PD, which may be of therapeutic relevance in
the future. Notably, however, contrasting results have also
been published reporting that adenoviral overexpression of
PGC-1𝛼 aggravated MPTP-mediated damage in mice [127]
and was ineffective against mutant 𝛼-synuclein-mediated
toxicity in rats [128] and that a sustained overexpression of
PGC-1𝛼 to high levels per se evoked the degeneration of
nigral neurons in rats [128].These findings necessitate further
investigations and draw the attention to the possibility that a
sustained overactivation of mitochondrial biogenesis aiming
to restore mitochondrial functions may also have deleterious
consequences on the long run.This issue needs to be clarified
in the future.
The search for effective neuroprotective compounds
capable of modifying the disease course in PD is still exten-
sive; as molecules targetingmitochondrial dysfunction in PD
though provided promising results in experimental models
of PD [129–131], they were ineffective in clinical trials [132].
In line with the data on a decreased function of PGC-1𝛼 in
PD and on the therapeutic potential of its activation, there
is a hope that transcriptional activation of mitochondrial
biogenesis and antioxidant responses via PGC-1𝛼 activation
may hold therapeutic value. A phase II safety and futility
clinical trial with the PPAR𝛾 agonist pioglitazone on patients
with early PDhas recently been completed, and the results are
about to be published in the near future (NCT01280123).
4.2. Huntington’s Disease. Huntington’s disease (HD) is a
monogenic, progressive neurodegenerative disease of auto-
somal dominant inheritance. The genetic alteration is the
expansion of CAG trinucleotide repeat sequence on the inter-
esting transcript 15 (IT15) gene on chromosome 4 encoding
huntingtin, with increasing number of repeat associating
with earlier onset and more rapid progression [133, 134].
The disease onset is usually between 40 and 50 years of
age, presenting with behavioral alterations and hyperkinesia
in the early stages, subsequently associating with pyramidal
symptoms, dystonia, dementia, and psychosis. The pathog-
nomonic alteration is the preferential loss of the striatal 𝛾-
aminobutyric acid (GABA)-ergic medium-sized spiny pro-
jection neurons (MSNs) and the presence of intracytoplasmic
and intranuclear protein inclusions of mutant huntingtin
widely distributed in neuronal as well as extraneuronal
tissues. The characteristic decreased activity of respiratory
complex II, especially in the striatum, has early linked HD to
mitochondrial dysfunction [135] (Figure 5). Since then, defi-
ciency in complex II is the most consistent and predominant
alteration reported in HD; however, the involvement of other
respiratory complexes has also been suggested [136, 137].
The concept of mitochondrial dysfunction mediating the
pathological process induced by mutant huntingtin is consis-
tent with an increased presence of oxidative stress [137–141],
which is well-reflected by the increased amount of mtDNA
mutations observed in HD patients [142]. Further alterations
supporting the primary role of mitochondrial dysfunction
in mediating the effects of mutant huntingtin include a
transcriptional [143] and/or functional [144] repression of
PGC-1𝛼, disturbances in mitochondrial trafficking [145], a
gradually decreasing mitochondrial number [146], and an
impairment of mitochondrial calcium handling [147] with an
enhanced sensitivity to calcium-induced opening of mPTP
and cytochrome c-mediated cell death [148, 149].
In line with the predominant biochemical alteration,
irreversible inhibition of complex II by 3-nitropropionic acid
effectively recapitulates most of the clinical and histopatho-
logical characteristics of HD, including the preferential neu-
ronal loss of GABAergic MSNs within the striatum [150, 151].
Similar alterations can be evoked via reversible complex II
blockade by malonate [152]. The relevance of complex II dys-
function in HD is highlighted by the fact that mutant hunt-
ingtin leads to decreased expression (at the protein level) of
the 30 kDa iron-sulfur (Ip) subunit and the 70 kDa FAD (Fp)
subunit of complex II in the striatum of HD patients [153]
and in vitro lentiviralmodels [153, 154]. Rather similar pattern
of alterations was found to underlie complex II deficiency in
transgenic HD mice and in a lentiviral model of HD in rats
[155]. Complex II dysfunction appears to be causative in HD
as its overexpression demonstrated marked restorative effect
in thesemodels [153–155]. Alterations in complex II assembly
were accompanied by reduced mitochondrial biogenesis in
transgenic animals, prompting the authors to suggest the
possible contribution of PGC-1𝛼 repression [155]. Indeed the
expression of PGC-1𝛼 has been found to be downregulated in
the striatum of HD patients [143, 144, 146, 156], in transgenic
HD animals [24, 143, 144, 157–159], and in in vitro HD
models [143, 156, 159, 160]. Correspondingly, the decreased
expression of several PGC-1𝛼 target genes has been identified
in the striatum of HD patients [144, 146] and transgenic HD
mice [144, 157, 158]. A possible mechanism through which
mutant huntingtin can lead to the downregulation of PGC-
1𝛼 can be secondary to its effect to enhance the expression
[161] and activity of NR2B subunit-containing NMDARs
[162], features characteristic of transgenic HD mice [163],
which in turn results in a decreased striatal CREB signaling
[163], and a subsequent downregulation of PGC-1𝛼 [164]. In
addition, a decreased expression of transducer of regulated
CREB-binding protein 1 (TORC1), an activator of CREB-
mediated PGC-1𝛼 expression, has been found in post mortem
HD striatum, in transgenic HD mice, and in an in vitro HD
model, which may contribute to the downregulation of PGC-
1𝛼 expression in HD [160], whereas others suggest that PGC-
1𝛼 repression may be secondary to the downregulation of
PPAR𝛾 in HD [159]. Supplementing the alterations in PGC-
1𝛼 expression in HD, Johri et al. reported decreased protein
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Figure 5:The involvement of mitochondrial dysfunction in Huntington’s disease. Complex II deficiency, the predominant electron transport
disorder in HD has long been linked to the deleterious effects of mutant huntingtin aggregation, a pathognomonic alteration in HD,
and inhibitors of complex II (such as 3-nitropropionic acid (3-NP) and malonate) are used in experimental modeling of the disease.
Disturbed OXPHOS in the affected cells can lead to the development of a vicious circle, eventually leading to cell death. Novel findings
link PGC-1𝛼 dysfunction to the pathogenesis of HD at multiple levels, the restoration of which may hold therapeutic value. (↑ = increased
presence/expression/activity; ↓= decreased presence/expression/activity; arrow= promotion; bulb-headed arrow= inhibition/deterioration.)
level of the functionally active N-truncated splice variant
of PGC-1𝛼 (NT-PGC-1𝛼) in the striatum of low-grade HD
patients and young asymptomatic transgenic N171-82Q and
R6/2 HD mice, whereas its level was found to be elevated in
high-grade HD patients and in older symptomatic transgenic
HD mice [156]. This pattern has been recently supported by
our study on transgenic N171-82Q HD mice at the mRNA
level, revealing a significantly upregulated expression of NT-
PGC-1𝛼 in both the striatum and overlying cortex of older
symptomatic HD mice compared to wild-type and young
HD counterparts [24]. These changes were accompanied
by a decreased expression of full-length PGC-1𝛼 in the
striatum and cortex of young transgenic mice, corresponding
to prior observations. A main novelty of this study included
a previously unidentified consistent elevation of both the
full-length and the N-truncated isoforms of PGC-1𝛼 in the
cerebellum of transgenic HD mice, which may underlie
the relative resistance of cerebellar neurons to degeneration
in HD [24]. This study further provided evidence for a
consistent striatal upregulation of both the full-length and
the N-truncated isoforms of PGC-1𝛼 following acute but not
chronic injury due to 3-nitropropionic acid intoxication in
mice [24].This possibly compensatory elevation corresponds
to prior findings of PGC-1𝛼 upregulation in response to
ROS challenge in vitro and highlights the role of PGC-
1𝛼 in concerting antioxidant responses [6, 23]. Supporting
a potential therapeutic relevance, a line of evidence sug-
gests that mechanisms associated with the upregulation of
PGC-1𝛼 can exert neuroprotection in experimental mod-
els of HD. Indeed, the administration of PPAR𝛾 agonist
thiazolidinediones (such as rosiglitazone and pioglitazone)
was proven to be protective in transgenic HD mice [158,
159, 165], in an intrastriatal quinolinic acid-induced rat toxin
model of HD [166], in 3-nitropropropionic acid-induced
murine toxin model of HD [167], and in in vitro HD models
[159, 165, 168]. Similarly, the pan-PPAR agonist bezafibrate
exerted protection in transgenic HD mice [169]. Further-
more, TORC1 activation displayed protective and restorative
effects on viability and mitochondrial functions in a striatal
HD cell line model exposed to 3-nitropropionic acid [160].
The protective effect of resveratrol, a polyphenol with potent
Sirt-1/PGC-1𝛼-activating properties, has also been demon-
strated in transgenic murine and nematode models [170], in
a 3-nitropropion acid-induced murine model [171], and in an
in vitro model of HD [170]. Notably, however, the potency
of resveratrol to significantly elevate the expression of PGC-
1𝛼 and its target genes within the striatum has recently been
questioned [172], which necessitates further investigations.
Considering that early attempts with mitochondria-targeted
molecules being neuroprotective in experimental HDmodels
[131, 173, 174] provided little success at the clinical level [132],
the transcriptional activation of mitochondrial respiration
andbiogenesismayhold novel therapeutic potential as amore
system-based approach. A phase III clinical trial with resver-
atrol is just about to recruit its participants (NCT02336633).
The corresponding set of evidence implicating a potential
pathogenetic role of PGC-1𝛼 repression in mitochondrial
dysfunction in HD as well as early observations of striatal
alterations in PGC-1𝛼-deficient mice [175, 176] suggested
that such animals may serve as experimental models for HD;
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however, findings of a recent detailed neuropathological
evaluation of mice lacking the expression of full-length
PGC-1𝛼 has indicated that it might not indeed be the case
and turned our attention to another group of diseases where
systemic mitochondrial dysfunction is pathognomonic
[122].
4.3. Mitochondrial Spongiform Leukoencephalopathies. Mito-
chondrial diseases are a group of multisystemic disorders
where the characteristic pathologies affecting organs with
high energy demand (i.e., brain, liver, heart, skeletal muscle,
and kidney) are due to mitochondrial dysfunction as a
consequence of a genetic alteration either in the mtDNA or
in the nDNA. The deleterious loss of functions may affect
several components of proper mitochondrial functioning,
including genes encoding respiratory complex subunits, pro-
teins responsible for mtDNA transcription/translation, mito-
chondrial tRNAs and rRNAs, and nuclear-encoded ancil-
lary proteins of mitochondrial function [177]. The diseases
are distributed to characteristic syndromes based on the
clinical manifestation and the observed neuropathological
alterations, including Kearns-Sayre syndrome, Leigh syn-
drome, mitochondrial encephalomyopathy, lactic acidosis
and stroke-like episodes (MELAS), myoclonic epilepsy with
ragged-red fibres (MERRF), neuropathy, ataxia, retinitis
pigmentosa (NARP), and mitochondrial neurogastrointesti-
nal encephalopathy (MNGIE) [178–181]. In these diseases,
impaired ATP production with various defects in respiratory
complexes and excess ROS production in the affected tis-
sues has widely been documented and has excessively been
reviewed [182].Though in somewhat different patterns, mito-
chondrial encephalopathies are collectively characterized by
various degrees of tissue vacuolation in the white and gray
matter of the CNS, accompanied by region-selective reactive
astrocytosis with or without neurodegeneration.
A number of genetically modified murine strains have
been developed to model diseases with mitochondrial
defects, however, with variable outcomes [122]. On the one
hand,many of the geneticmodifications lead to embryonic or
early postnatal mortality due to multisystemic insufficiency
(e.g., complete knockouts of CREB [183], Tfam [184], NRF-
1 [185], NRF-2 [186], ERR𝛾 [187], POLG1 [188], synthesis of
cytochrome 𝑐 oxidase 2 (SCO2) [189], and optic atrophy 1
(OPA1) [190]). On the other hand, a remarkable proportion
of viable models, surprisingly, does not have any patho-
logical changes in the CNS (e.g., complete knockouts of
adenine nucleotide translocator 1 (ANT1) [191], PPAR𝛾 [192],
ERR𝛼 [193], and SURF1 [194]; ΔmtDNA Mito-Mice [195];
and Twinkle mutant “Deletor” mice [196]). Genetic models
exhibiting a neuropathology closely reminiscent of human
mitochondrial leukoencephalopathies include mice deficient
in Mn-SOD [197], in thymidine phosphorylase and uridine
phosphorylase (TP/UP) [198], and in NADH dehydroge-
nase [ubiquinone] iron-sulfur protein 4 (NDUFS4) [199].
In addition to these, our recent neuropathological analysis
on mice deficient in the expression of full-length PGC-
1𝛼 revealed widespread spongy vacuolation predominating
in the white matter of the striatum, thalamus, cerebellum,
and the brainstem, accompanied by moderate to severe
reactive astrogliosis in the pontomedullary brainstem and the
cerebellar nuclei, corresponding to a pattern of alterations
characteristic of the spongiform leukoencephalopathy seen
in Kearns-Sayre syndrome [122].This is especially interesting
in light of the facts that experimental animals used for
modeling cardiomyopathy in Kearns-Sayre syndrome are
the tissue-specific knockouts of Tfam [200, 201], a gene
under the regulation PGC-1𝛼, and the expression of which is
severely downregulated in PGC-1𝛼-deficient mice [119, 175].
Notably, no indirect or direct signs indicative striatal neu-
ronal degeneration and/or loss were observed in our study
[122], which corresponds to the independent observations of
Lucas et al. [202], both publications drawing the conclusion
that PGC-1𝛼-deficiency per se is not sufficient to evoke
HD-like pathology, contrasting to what had previously been
suggested.
Considering the spectrum of roles of PGC-1𝛼 in reg-
ulating and promoting mitochondrial functions and the
fact that a number of genes involved in disease-causing
mutations and/or that involved in modeling mitochondrial
disease have direct or indirect interactions with PGC-1𝛼 (e.g.,
ANT-1, POLG1, Tfam, NRF-1, NRF-2, PPARs, ERRs, Mn-
SOD, and CREB), the rationale for PGC-1𝛼 induction to
provide symptomatic benefit in these currently intractable
groups of diseases can be accepted [203]. Indeed, transgenic
overexpression or bezafibrate-induced expression of PGC-1𝛼
delayed the onset of symptoms in a cytochrome 𝑐 oxidase-
deficient murine model of mitochondrial myopathy [204].
Similarly, transgenic overexpression of PGC-1𝛼 ameliorated
the phenotype and increased the activity of mitochondrial
respiratory complexes in POLG1 mutant “Mutator” mice
[205]. Furthermore, adenoviral overexpression of PGC-1𝛼
partially restored respiratory deficits in fibroblasts obtained
from patients with mitochondrial disease of various origin
(though to different efficacy) and in MELAS cybrids [206].
These altogether suggest a potential therapeutic relevance
of boosting mitochondrial biogenesis via PGC-1𝛼-mediated
approaches in diseases with genetic mitochondrial disorder.
5. Concluding Remarks
Since the revelation of the essential role electrons, originating
from reducing equivalents that arise from cytosolic and/or
mitochondrial metabolic processes, in cellular bioenergetics
via their flow through metal-containing electron transport
complexes in the mitochondrial inner membrane, an armada
of evidence has accumulated linking the impaired function of
this system to degenerative diseases of the CNS. While initial
attempts to compensate for such alterations showed as much
promise at the experimental level as deep disappointment
they caused at the clinical level, novel strategies with more
system-based approaches aiming to render protection via
improving mitochondrial bioenergetics at a transcriptional
level may open up new therapeutic perspectives and boost
pharmacological research. With more and more evidence
linking PGC-1𝛼 and its target genes to the pathogene-
sis of neurodegenerative diseases including PD, HD, and
mitochondrial disorders, pharmacological manipulations to
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restore and/or activate PGC-1𝛼may provide valuable tools in
the therapy of these currently intractable diseases.
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